Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

О нас

Контакты

[email protected]

Мы в соцсетях

Instagram
Telegram
LinkedIn

Все права защищены.

Условия использования

Главная
Рынки
Скринер
Новости
О нас

MGNX - MacroGenics, Inc. Последние новости | Finranks

Home

MGNX

M

MacroGenics, Inc. (MGNX)

NMS – Цена в реальном времени. Валюта: USD

2.93

-0.25 (-7.86%)

При закрытии: Mar 27, 2026, 4:00 PM EDT

2.86

-0.07 (-2.39%)

После закрытия: Mar 27, 2026, 6:14 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

MacroGenics, Inc. (MGNX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

MacroGenics, Inc. (MGNX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

MacroGenics, Inc. (MGNX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

MacroGenics (MGNX) Reports Q4 Loss, Tops Revenue Estimates

MacroGenics (MGNX) Reports Q4 Loss, Tops Revenue Estimates

MacroGenics (MGNX) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to a loss of $0.25 per share a year ago.

MacroGenics Reports 2025 Financial Results and Highlights Upcoming Planned Data Disclosures

MacroGenics Reports 2025 Financial Results and Highlights Upcoming Planned Data Disclosures

ROCKVILLE, Md., March 09, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress, reported financial results for the year ended December 31, 2025, and highlighted anticipated data disclosure timelines for its product pipeline.

MacroGenics to Participate in Upcoming Investor Conferences

MacroGenics to Participate in Upcoming Investor Conferences

ROCKVILLE, MD, Feb. 26, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company's management team will participate in the following investor conferences in March: TD Cowen 46th Annual Health Care Conference (Boston, MA). MacroGenics' President and CEO, Eric Risser, will participate in a hybrid presentation and fireside chat on Tuesday, March 3, at 3:10 pm ET.

MacroGenics Announces Pausing of Enrollment of New Study Participants in LINNET Trial

MacroGenics Announces Pausing of Enrollment of New Study Participants in LINNET Trial

FDA has placed partial clinical hold on LINNET study of lorigerlimab in gynecologic cancer FDA has placed partial clinical hold on LINNET study of lorigerlimab in gynecologic cancer

MacroGenics to Participate in the 8th Annual Evercore Healthcare Conference

MacroGenics to Participate in the 8th Annual Evercore Healthcare Conference

ROCKVILLE, MD, Nov. 25, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that Eric Risser, President and CEO of MacroGenics, will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Thursday, December 4, at 7:55 am ET in Miami, FL. A webcast of the presentation may be accessed under "Events & Presentations" in the Investor Relations section of MacroGenics' website at http://ir.macrogenics.com/events.cfm.

MacroGenics (MGNX) Q3 Earnings and Revenues Surpass Estimates

MacroGenics (MGNX) Q3 Earnings and Revenues Surpass Estimates

MacroGenics (MGNX) came out with quarterly earnings of $0.27 per share, beating the Zacks Consensus Estimate of a loss of $0.48 per share. This compares to earnings of $0.9 per share a year ago.

Видео

No Data

There is no data to display

Пресс-релизы

MacroGenics Reports 2025 Financial Results and Highlights Upcoming Planned Data Disclosures

MacroGenics Reports 2025 Financial Results and Highlights Upcoming Planned Data Disclosures

ROCKVILLE, Md., March 09, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress, reported financial results for the year ended December 31, 2025, and highlighted anticipated data disclosure timelines for its product pipeline.

MacroGenics Announces Pausing of Enrollment of New Study Participants in LINNET Trial

MacroGenics Announces Pausing of Enrollment of New Study Participants in LINNET Trial

FDA has placed partial clinical hold on LINNET study of lorigerlimab in gynecologic cancer FDA has placed partial clinical hold on LINNET study of lorigerlimab in gynecologic cancer

MacroGenics to Participate in the 8th Annual Evercore Healthcare Conference

MacroGenics to Participate in the 8th Annual Evercore Healthcare Conference

ROCKVILLE, MD, Nov. 25, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that Eric Risser, President and CEO of MacroGenics, will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Thursday, December 4, at 7:55 am ET in Miami, FL. A webcast of the presentation may be accessed under "Events & Presentations" in the Investor Relations section of MacroGenics' website at http://ir.macrogenics.com/events.cfm.

MacroGenics Reports Third Quarter 2025 Financial Results and Provides Update on Corporate Progress

MacroGenics Reports Third Quarter 2025 Financial Results and Provides Update on Corporate Progress

ROCKVILLE, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today reported financial results for the third quarter ended September 30, 2025, and provided an update on its recent corporate progress.